We are live on ! Find out more
IRD

Opus Genetics

40 hedge funds and large institutions have $8.07M invested in Opus Genetics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

468% more call options, than puts

Call options by funds: $1.07M | Put options by funds: $188K

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

33% more funds holding

Funds holding: 3040 (+10)

2.61% more ownership

Funds ownership: 9.94%12.54% (+2.6%)

6% less capital invested

Capital invested by funds: $8.62M → $8.07M (-$547K)

Holders
40
Holders Change
+10
Holders Change %
+33.33%
% of All Funds
0.62%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
12
Reduced
6
Closed
3
Calls
$1.07M
Puts
$188K
Net Calls
+$879K
Net Calls Change
+$842K

IRD Hedge Fund Activity: Q4 2021 in Review

40 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2021, worth a combined $8.07M — down 6.3% from $8.62M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IRD positions and 3 closed out — a net gain of 10 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Two Sigma Advisers, adding an estimated $1.1M. The largest seller was Vanguard Group, cutting an estimated $1.11M.

  • 40 institutional investors held Opus Genetics (IRD) as of Q4 2021, up from 30 in Q3 2021.
  • Funds reported $8.07M of Opus Genetics stock for Q4 2021, down 6.3% quarter-over-quarter.
  • 13 funds opened new Opus Genetics positions in Q4 2021 and 3 closed out, a net change of +10 holders.
  • The largest Opus Genetics buyer in Q4 2021 was Two Sigma Advisers, an estimated $1.1M added.
  • The largest Opus Genetics seller in Q4 2021 was Vanguard Group, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2021.